Theravance Biopharma Inc
NASDAQ: TBPH0.00 n/a
+0.00%(+0.00)
Key facts
- Exchange
- NASDAQ
- Sector
- Healthcare
- Industry
- Biotechnology
- CEO
- Rick E. Winningham
- Employees
- 90
- Headquarters
- South San Francisco, United States
- IPO year
- 2014
- Market cap
- $875.4M
- Website
- https://www.theravance.com
Loading TBPH…
Loading profile data…Frequently asked questions about TBPH
What does Theravance Biopharma Inc (TBPH) do?
Theravance Biopharma, Inc., a biopharmaceutical company, develops and commercializes medicines in the United States. It offers YUPELRI, an once-daily, nebulized long-acting muscarinic antagonist for the treatment of chronic obstructive pulmonary disease (COPD); and Ampreloxetine an investigational, once-daily norepinephrine reuptake inhibitor, W...
Where does TBPH trade?
Theravance Biopharma Inc (TBPH) trades on the NASDAQ.
What sector is TBPH in?
Theravance Biopharma Inc (TBPH) operates in the Healthcare sector, specifically in the Biotechnology industry.
Who is the CEO of Theravance Biopharma Inc?
Rick E. Winningham is the chief executive officer of Theravance Biopharma Inc (TBPH).
Where is Theravance Biopharma Inc headquartered?
Theravance Biopharma Inc is headquartered in United States.
Does TBPH pay a dividend?
Theravance Biopharma Inc (TBPH) does not currently pay a regular dividend. Check the dividends tab for any historical or special distributions.
When did TBPH go public?
Theravance Biopharma Inc (TBPH) completed its initial public offering in 2014.